Here’s What Hedge Funds Think About Meridian Bioscience, Inc. (VIVO)
Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved, lost nearly 40% of its value at one point in 2018. Although hedge funds are not...
Edited Transcript of VIVO earnings conference call or presentation 30-Apr-19 2:00pm GMT
Q2 2019 Meridian Bioscience Inc Earnings Call
Meridian Bioscience's (VIVO) CEO Jack Kenny Q2 2019 Earnings and Strategic Acquisition Conference - Call Tr
Meridian Bioscience Inc. (VIVO) Q2 2019 Earnings and Strategic Acquisition Conference Call April 30, 2019, 10:00 AM ET Company Participants Eric Rasmussen Chief Financial Officer Jack Kenny...
Cincinnati public company will acquire Canadian firm
One of Greater Cincinnati’s largest public companies is planning an acquisition that could have a price tag of up to $120 million.
Meridian Bioscience (VIVO) Q2 Earnings and Revenues Top Estimates
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 26.67% and 0.46%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Meridian Bioscience Reports Second Quarter 2019 Operating Results, Suspends Quarterly Cash Dividend, and Pr
CINCINNATI, April 30, 2019 -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter and first six months ended March 31, 2019..
Meridian Bioscience Announces Agreement to Acquire Business of GenePOC; Adds State-of-the-Art Molecular Dia
Meridian Bioscience, Inc. (VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced it has entered into a definitive agreement to acquire the business of GenePOC...
Meridian Bioscience: Fiscal 2Q Earnings Snapshot
On a per-share basis, the Cincinnati-based company said it had profit of 17 cents. Earnings, adjusted for costs related to mergers and acquisitions and non-recurring costs, were 19 cents per share. The...
Meridian Bioscience suspends quarterly cash dividend
Meridian Bioscience ( VIVO -14% ) suspends quarterly cash dividend in connection with the announcement of the Companys agreement to acquire the business of GenePOC Inc. and decision to allocate capital...
Meridian Bioscience, Inc. 2019 Q2 - Results - Earnings Call Slides
The following slide deck was published by Meridian Bioscience, Inc. in conjunction with their 2019 Q2 earnings Read more …
ABcann's group of companies will be the first to produce repeatable, standardized, plant-based medicines worldwide.
ABcann will produce products with integrity in a customer focused culture where social responsibility and environmental impacts are mandated.